Development and application of a biorelevant dissolution method using USP apparatus 4 in early phase formulation development.
Dissolution testing is frequently used to determine the rate and extent at which a drug is released from a dosage form, and it plays many important roles throughout drug product development. However, the traditional dissolution approach often emphasizes its application in quality control testing and usually strives to obtain 100% drug release. As a result, dissolution methods are not necessarily biorelevant and meaningful application of traditional dissolution methods in the early phases of drug product development can be very limited. This article will describe the development of a biorelevant in vitro dissolution method using USP apparatus 4, biorelevant media, and real-time online UV analysis. Several case studies in the areas of formulation selection, lot-to-lot variability, and food effect will be presented to demonstrate the application of this method in early phase formulation development. This biorelevant dissolution method using USP apparatus 4 provides a valuable tool to predict certain aspects of the in vivo drug release. It can be used to facilitate the formulation development/selection for pharmacokinetic (PK) and clinical studies. It may also potentially be used to minimize the number of PK studies, and to aid in the design of more efficient PK and clinical studies.
Fang
Jiang B
JB
Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA. fang@amgen.com
Robertson
Vivian K
VK
Rawat
Archana
A
Flick
Tawnya
T
Tang
Zhe J
ZJ
Cauchon
Nina S
NS
McElvain
James S
JS
D000818:Animals; D001682:Biological Availability; D002626:Chemistry, Pharmaceutical / Q000295:instrumentation / Q000379:methods*; D004304:Dosage Forms; D018565:Food-Drug Interactions; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007408:Intestinal Absorption; D010599:Pharmacokinetics; D012995:Solubility
D004304:Dosage Forms